Depemokimab (Exdensur) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics · 16.03.2026 · 68 (1750) · 44-46
DOI: 10.58347/tml.2026.1750b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 16.03.2026.
Abstract (Originalsprache)
The FDA has approved depemokimab (Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala) and reslizumab (Cinqair) and the IL-5 receptor alpha antagonist benralizumab (Fasenra) were approved earlier.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Depemokimab (Exdensur) for Severe Eosinophilic Asthma. The Medical Letter on Drugs and Therapeutics, 68(1750), 44-46. https://doi.org/10.58347/tml.2026.1750b
Vancouver
Depemokimab (Exdensur) for Severe Eosinophilic Asthma. The Medical Letter on Drugs and Therapeutics. 2026;68(1750):44-46. doi:10.58347/tml.2026.1750b
BibTeX
@article{euvimed2026,
title = {Depemokimab (Exdensur) for Severe Eosinophilic Asthma},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1750},
pages = {44--46},
doi = {10.58347/tml.2026.1750b}
}
EUVIMED